Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
Janux Therapeutics To Host Virtual Event On Monday, December 2, 2024, At 4:30 PM ET Discussing Updated Clinical Data In Phase 1a Dose Escalation For JANX007 In MCRPC And Doses Selected For Phase 1b Expansion Studies
The virtual event will take place on Monday, December 2, 2024, at 4:30 PM ET
虛擬活動將於2024年12月2日星期一下午4:30（東部時間）舉行。
Janux Therapeutics, Inc. (NASDAQ:JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced it will host a virtual event on Monday, December 2, 2024, at 4:30 PM ET.
Janux Therapeutics, Inc. （納斯達克:JANX）（Janux）是一家臨牀階段的生物製藥公司，通過將其專有科技應用於腫瘤激活t 電芯劫持劑（TRACTr）和腫瘤激活免疫調節劑（TRACIr）平台，開發一系列新型免疫療法。今天宣佈，將於2024年12月2日星期一下午4:30（東部時間）舉行虛擬活動。
David Campbell, Ph.D., President & Chief Executive Officer, will provide an update on JANX007 Phase 1a dose escalation data and doses selected for Phase 1b expansion studies in adult subjects with metastatic castration-resistant prostate cancer (mCRPC).
大衛·坎貝爾（David Campbell），博士，董事會主席兼首席執行官，將對JANX007第1a期劑量擴大數據以及爲轉移性去勢抵抗性前列腺癌（mCRPC）成人受試者選擇的第10億期擴展研究的劑量進行更新。
